DATA SHEET

AURO-ONDANSETRON
Ondansetron hydrochloride dihydrate
4 and 8 mg film coated tablets

PRESENTATION

AURO-ONDANSETRON ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablets
White to off-white, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘01’ on the other side.

AURO-ONDANSETRON ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablets
Yellow coloured, oval shaped, film-coated tablets debossed with ‘E’ on one side and ‘02’ on the other side.

INDICATIONS

AURO-ONDANSETRON is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. AURO-ONDANSETRON is also indicated for the prevention of post-operative nausea and vomiting.

DOSAGE AND ADMINISTRATION

Chemotherapy and radiotherapy induced nausea and vomiting

Adults
The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used.

Emetogenic Chemotherapy and Radiotherapy
The recommended oral dose is 8 mg 1-2 hours before treatment, followed by 8 mg orally 12 hours later.

To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with Ondansetron should be continued for up to 5 days after a course of treatment. The recommended oral dose is 8 mg to be taken twice daily.

Highly Emetogenic Chemotherapy
Ondansetron can be given by oral, intravenous or intramuscular administration.

To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with Ondansetron should be continued for up to 5 days after a course of treatment. The recommended oral dose is 8 mg to be taken twice daily.
Children and Adolescents (aged 6 months to 17 years)
In children with a body surface area of 0.6 to 1.2 m² ondansetron is administered as a single intravenous dose of 5 mg/m² immediately before chemotherapy, followed by 4 mg orally twelve hours later. 4 mg orally twice daily can be continued for up to 5 days after a course of treatment.

For children with a body surface area of greater than 1.2 m² an initial i.v. dose of 8 mg is administered immediately before chemotherapy, followed by 8 mg orally 12 hours later. 8 mg orally twice daily can be continued for up to five days after a course of treatment.

Alternatively, in children aged 6 months or older, Ondansetron is administered as a single i.v. dose of 0.15 mg/kg (not to exceed 8 mg) immediately before chemotherapy. This dose may be repeated every four hours for a total of three doses. 4 mg orally twice daily can be continued for up to five days after a course of treatment. Adult doses must not be exceeded.

Elderly
Ondansetron is well tolerated by patients over 65 years and no alteration of dosage, dosing frequency or route of administration are required.

Post-operative nausea and vomiting
Adults
For prevention of post-operative nausea and vomiting, the recommended oral dose is 16 mg given one hour prior to anaesthesia.

For treatment of established post-operative nausea and vomiting Ondansetron administration by injection is recommended.

Children and Adolescents (aged 1 month to 17 years)
No studies have been conducted on the use of orally administered Ondansetron in the prevention or treatment of post-operative nausea and vomiting; slow intravenous injection is recommended for this purpose.

Use in the Elderly
There is limited experience in the use of Ondansetron in the prevention and treatment of post-operative nausea and vomiting in the elderly, however Ondansetron is well tolerated in patients over 65 years receiving chemotherapy.

Patients with renal impairment
No alteration of daily dosage or frequency of dosing, or route of administration are required.

Patients with hepatic impairment
Clearance of Ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded

Patients with poor sparteine/debrisoquine metabolism
The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will
give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing are required.

**CONTRAINDICATIONS**

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

Hypersensitivity to any component of the preparation.

**WARNINGS AND PRECAUTIONS**

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT₃ receptor antagonists.

Ondansetron prolongs the QT interval in a dose-dependent manner. In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.

Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.

As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

**Pregnancy and Lactation**

The safety of ondansetron for use in human pregnancy has not been established. Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo, or foetus, the course of gestation and peri- and post-natal development. However as animal studies are not always predictive of human response the use of ondansetron in pregnancy is not recommended.

Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving ondansetron should not breast-feed their babies.

**Effects on ability to drive and use machines**

In psychomotor testing ondansetron does not impair performance nor cause sedation.

**ADVERSE EFFECTS**

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Very common, common and uncommon events were generally determined from clinical trial
data. The incidence in placebo was taken into account. Rare and very rare events were generally determined from post-marketing spontaneous data.

The following frequencies are estimated at the standard recommended doses of ondansetron according to indication and formulation.

**Immune system disorders**
Rare: Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.

**Nervous system disorders**
Very common: Headache.

Uncommon: Seizures, movement disorders (including extrapyramidal reactions such as oculogyric crisis, dystonic reactions and dyskinesia have been observed without definitive evidence of persistent clinical sequelae).

Rare: Dizziness during rapid i.v. administration.

**Eye disorders**
Rare: Transient visual disturbances (eg. blurred vision) predominantly during i.v. administration.

Very rare: transient blindness predominantly during intravenous administration.

The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.

**Cardiac disorders**
Uncommon: Arrhythmias, chest pain with or without ST segment depression, bradycardia. Rare: QTc prolongation (including Torsade de Pointes)

**Vascular disorders**
Common: Sensation of warmth or flushing.

Uncommon: Hypotension.

**Respiratory, thoracic and mediastinal disorders**
Uncommon: Hiccups.

Gastrointestinal disorders

Common: Constipation.

**Hepatobiliary disorders**
Uncommon: Asymptomatic increases in liver function tests#.
# These events were observed commonly in patients receiving chemotherapy with cisplatin.

**General disorders and administration site conditions**

Common: Local i.v. injection site reactions.

**INTERACTIONS**

**Interaction with other medicinal products and other forms of interaction**

There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly coadministered with it. Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, frusemide, tramadol or propofol.

Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.

Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities (see WARNINGS & PRECAUTIONS).

**Apomorphine**

Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.

**Phenytoin, Carbamazepine and Rifampicin**

In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.

**Tramadol**

Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.

**OVERDOSAGE**

There is limited experience of ondansetron overdose. In the majority of cases symptoms were similar to those already reported in patients receiving recommended doses (see Undesirable effects). There is no specific antidote for ondansetron, therefore in cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.

The use of ipecacuanha to treat overdose with ondansetron is not recommended as patients are unlikely to respond due to the anti-emetic action of Ondansetron itself. Ondansetron prolongs QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.
PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties

Ondansetron is a potent, highly selective 5HT$_3$ receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT$_3$ receptors. Ondansetron blocks the initiation of this reflex.

Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT$_3$ receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.

Ondansetron does not alter plasma prolactin concentrations.

Pharmacokinetic Properties

Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations are attained approximately 1.5 hours after dosing. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses.

Bioavailability is slightly enhanced by the presence of food but unaffected by antacids. The disposition of ondansetron following oral, intramuscular or intravenous dosing is similar with a terminal elimination half life of about 3 hours and steady state volume of distribution of about 140L. Ondansetron is not highly protein bound (70-76%). Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron's pharmacokinetics. The pharmacokinetic properties of ondansetron are unchanged on repeat dosing. Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age-related increases in both oral bioavailability and half-life of ondansetron.

Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).

In a clinical study, 51 paediatric patients aged 1 to 24 months received either 0.1 or 0.2 mg/kg ondansetron prior to undergoing surgery. Patients aged 1 to 4 months had a clearance when normalised to body weight that was approximately 30% slower than in patients aged 5 to 24 months but comparable to the patients aged 3 to 12 years. The half-life in the 1 to 4 month patient population was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. No dose adjustment is necessary for patients aged 1 to 4 months as only a single i.v. dose of ondansetron is recommended for the treatment of postoperative nausea and vomiting. The differences in pharmacokinetic parameters can be explained in part by the higher volume of distribution in the 1 to 4 month patient population.
In a study of 21 paediatric patients aged between 3 and 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron following a single intravenous dose of 2 mg (3-7 years old or 4 mg (8-12 years old) were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were similar between the different age group populations. Use of weight-based dosing (0.1 mg/kg up to 4mg maximum) compensates for these changes and is effective in normalising systemic exposure in paediatric patients.

Population pharmacokinetic analysis was performed on 74 patients aged 6 to 48 months following administration of 0.15 mg/kg i.v. ondansetron every 4 hours for three doses for the treatment of chemotherapy induced nausea and vomiting and 41 surgery patients aged 1 to 24 months following administration of a single 0.1 mg/kg or 0.2 mg/kg i.v. dose of ondansetron. Based on the population pharmacokinetic parameters for subjects aged 1 month to 48 months, administration of a 0.15 mg/kg i.v. dose of ondansetron every 4 hours for 3 doses would result in a systemic exposure (AUC) comparable to that observed in paediatric surgery subjects aged 5 to 24 months and previous paediatric studies in cancer (aged 4 to 18 years) and surgical (aged 3 to 12 years) subjects, at similar doses.

In patients with moderate renal impairment (creatinine clearance 15-60 mL/min), both systemic clearance and volume of distribution are reduced, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 h). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron's pharmacokinetics to be essentially unchanged. In patients with severe hepatic impairment, ondansetron's systemic clearance is markedly reduced with prolonged elimination half-lives (15-32 h) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism.

Preclinical Safety Data
No additional data of relevance.

PHARMACEUTICAL PRECAUTIONS

Instructions for Use/Handling
Store below 25 °C.

MEDICINE CLASSIFICATION
Prescription Medicine.

PACKAGE QUANTITIES
AURO-ONDANSETRON ondansetron as hydrochloride dihydrate 4 & 8 mg are presented in 4, 10, 30* & 90* tablets blister packs.

*not marketed
FURTHER INFORMATION

Ondansetron is a potent, highly selective 5 HT₃ receptor-antagonist, and has the following chemical name:

\[(3RS)-9\text{-Methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride dihydrate.}\]

Ondansetron hydrochloride dihydrate is a white or almost white powder. It is sparingly soluble in water, alcohol, soluble in methanol and slightly soluble in methylene chloride.

Excipients

In addition to ondansetron hydrochloride dihydrate, AURO-ONDANSETRON tablet contains the following inactive ingredients: lactose anhydrous, cellulose-microcrystalline, starch-pregelatinised maize and magnesium stearate. The 4 mg tablet also contains triacetin, titanium dioxide and hypromellose. The 8 mg tablet also contains opadry yellow 03K52033 (PI-ARTG No. 106488).

NAME AND ADDRESS

Aurobindo Pharma NZ Limited
64 Saddleback Grove
Karori Wellington 6012
NEW ZEALAND

DATE OF PREPARATION

29 August 2013